For a probing discussion detailing the American Lung Association’s recent 2024 “State of Lung Cancer” report, we are joined by esteemed thoracic medical oncologist Dr. Jacob Sands of Dana-Farber Cancer Institute and Harvard Medical School. Offering insight into actionable targeted mutations, Dr. Sands addresses how precision oncology is fundamentally changing lung cancer diagnosis and treatment.
The novel immunotherapy drugs, though proven to be safe and effective with significant improvements in response and survival rates, have challenges as well—this episode covers the gamut.
Episode Highlights
0:00 Start
1:00 Topic of discussion
2:42 Introducing Jacob Sands, MD
3:39 NCCN guidelines for lung cancer
6:51 Recently-approved drugs for lung cancer
13:46 Patient responses to targeted mutations
17:58 Off-target side effects with drugs
21:34 State of Lung Cancer report
23:04 Estimated number of candidates for targeted therapies
26:13 Insurance coverage for biomarker testing
28:12 Other issues with ordering biomarkers
31:20 Closing comments
32:36 Outro
Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast
